Statalist


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: st: Re: compound outcome variables (not specifically Stata-related)


From   Diego Navarro <[email protected]>
To   [email protected]
Subject   Re: st: Re: compound outcome variables (not specifically Stata-related)
Date   Sat, 24 Jan 2009 15:44:13 -0200

I recently finished a project for a private consulting shop where I used principal component analysis to compress a number of socioeconomic outcome measurements (GDP per capita, unemployment, diverse measures of education, Gini and Theil indexes, etc.) into a single State Development Index that was computed for states in Brazil. (It's like states in the USA). We're actually getting it published into the mainstream press!

Anyway, that's a datapoint for people treating multiple outcome issues with Stata.

--
Diego Navarro
(21) 2559-5620

"Writing is not really about meaning, but about land-surveying and cartography, particularly of lands yet to come" (Mille Plateaux #1.11)

“The first step is to measure what can be easily measured. This is okay as far as it goes. The second step is to disregard that which cannot be measured, or give it an arbitrary quantitative value. This is artificial and misleading. The third step is to presume that what cannot be measured really is not very important. This is blindness. The fourth step is to say that what cannot be measured does not really exist. This is suicide.” (Daniel Yankelovich, 1973)




On 24/01/2009, at 02:03, Joseph Coveney wrote:

A few years ago, Prof. Gary G. Koch (University of North Carolina at Chapel
Hill) gave a talk here in Tokyo on his researches into the statistical
handling of "multiple endpoints" (the term he used for what you describe) in clinical trials. One of his articles might be a good entry point into the literature on the matter. He gave his talk under the auspices of the Drug Information Association, an organization that is largely focused on industrial product-development activities (viz., pharmaceuticals and biologics), but the approaches he described can be applied more generally, e.g., evaluating benefits of medical or surgical treatments, or life-style changes. Tony Lachenbruch already mentioned the positions that the U.S. Food and Drug
Administration takes for so-called co-primary outcomes and multiple
primary outcomes in the context of granting or denying sales authorizations for medical products. Professor Koch's talk covered those, but also broached the topic of using the endpoints in a compound, or joint, manner (as if combining them into a single index of treatment response), and addressed some of the various approaches of doing that and their associated problems. The U.S. Food and Drug Administration allows these latter approaches in selected cases, for example, I believe that there is such a compounded index for
rheumatoid arthritis that is widely and frequently used.

Joseph Coveney

Christopher W. Ryan wrote:

I would like to try to do a journal club session for my family practice residents on the uses, and especailly the pitfalls, of compound outcome
variables, like "stroke or myocardial infarction or coronary bypass
surgery." They appear frequently in clinical trial literature.  Can
anyone recommend any good articles discussing the issues?  Thanks.



*
*   For searches and help try:
*   http://www.stata.com/help.cgi?search
*   http://www.stata.com/support/statalist/faq
*   http://www.ats.ucla.edu/stat/stata/







*
*   For searches and help try:
*   http://www.stata.com/help.cgi?search
*   http://www.stata.com/support/statalist/faq
*   http://www.ats.ucla.edu/stat/stata/



© Copyright 1996–2024 StataCorp LLC   |   Terms of use   |   Privacy   |   Contact us   |   What's new   |   Site index